Cogent Biosciences (COGT) Expected to Announce Earnings on Monday

Cogent Biosciences (NASDAQ:COGT) is anticipated to release its earnings data before the market opens on Monday, February 24th. Analysts expect Cogent Biosciences to post earnings of ($0.59) per share for the quarter.

Cogent Biosciences Trading Down 1.1 %

NASDAQ COGT opened at $8.00 on Friday. Cogent Biosciences has a 12 month low of $5.73 and a 12 month high of $12.61. The stock has a 50 day moving average of $8.25 and a 200-day moving average of $9.59. The company has a market cap of $883.68 million, a PE ratio of -3.23 and a beta of 1.77.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright lowered their price objective on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Needham & Company LLC cut Cogent Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $11.00 price objective on shares of Cogent Biosciences in a research note on Monday, January 13th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.33.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.